Health ❯ Medicine ❯ Pharmacology

Drug Development

Alzheimer's Disease Antibiotics Cancer Treatment Targeted Therapy Weight Loss Drugs Targeted Therapies GLP-1 Agonists Obesity Treatments Weight Loss Therapies Aldosterone Inhibitors Enzyme Inhibitors Blockbuster Drugs Anti-Obesity Medications Combination Therapies Aspirin Gantenerumab Novo Nordisk Antibiotic Resistance Male Contraceptives Clinical Trials GLP-1 Mimicking Drugs Fluorous Lipopeptides Future Therapies for Parkinson's Disease Alzheimer's Treatment Eli Lilly's Drug Portfolio Nerve Growth Acceleration Disulfiram Bioactive Compounds Oral Drug Delivery Baxdrostat Pain Management Anesthetic Compounds Protein Degradation PPARy Agonists New Analgesics Opioid Alternatives Target Identification Inhaled Therapies ACE Inhibitors Cholesterol Depletion Rare Diseases Obesity Treatment Type 2 Diabetes Anti-Obesity Drugs Transcriptional Plasticity Regulators SUMO2 Inhibitors Host-Directed Therapy CETP Inhibitors Biocompatibility Obesity Drugs Targeted Covalent Inhibitors Biased Modulators Matrix-Based Therapy Nerandomilast Cancer Therapeutics Vitamin K Analogues Natural Compounds Selective Drugs Molecular Glues Tissue Repair AstraZeneca Ribosome Inhibition Combination Therapy Opioid Overdose Treatment KCL-HO-1i Hormone Therapy Toxin Research Muscle Disorder Treatments

Nature Study Shows Intracellular GPCR Targeting Can Direct Signaling

The findings point to a predictable route for designing safer, receptor‑specific medicines.

AstraZeneca’s Baxdrostat Hits Phase 3 Goal With 24‑Hour Blood‑Pressure Cuts

FDA Clears UCLA’s ENPP1-Blocking Antibody AD-NP1 for First-in-Human Trial